JP2009536201A5 - - Google Patents

Download PDF

Info

Publication number
JP2009536201A5
JP2009536201A5 JP2009509615A JP2009509615A JP2009536201A5 JP 2009536201 A5 JP2009536201 A5 JP 2009536201A5 JP 2009509615 A JP2009509615 A JP 2009509615A JP 2009509615 A JP2009509615 A JP 2009509615A JP 2009536201 A5 JP2009536201 A5 JP 2009536201A5
Authority
JP
Japan
Prior art keywords
rage
formulation
fusion protein
seq
reconstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009509615A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009536201A (ja
JP5558810B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/010125 external-priority patent/WO2007130302A2/en
Publication of JP2009536201A publication Critical patent/JP2009536201A/ja
Publication of JP2009536201A5 publication Critical patent/JP2009536201A5/ja
Application granted granted Critical
Publication of JP5558810B2 publication Critical patent/JP5558810B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009509615A 2006-05-05 2007-04-25 Ｒａｇｅ融合タンパク質、製剤及びその使用方法 Expired - Fee Related JP5558810B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79845506P 2006-05-05 2006-05-05
US60/798,455 2006-05-05
PCT/US2007/010125 WO2007130302A2 (en) 2006-05-05 2007-04-25 Rage fusion proteins, formulations, and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2009536201A JP2009536201A (ja) 2009-10-08
JP2009536201A5 true JP2009536201A5 (https=) 2010-06-17
JP5558810B2 JP5558810B2 (ja) 2014-07-23

Family

ID=38521887

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009509615A Expired - Fee Related JP5558810B2 (ja) 2006-05-05 2007-04-25 Ｒａｇｅ融合タンパク質、製剤及びその使用方法

Country Status (21)

Country Link
US (2) US7981424B2 (https=)
EP (2) EP2021474A2 (https=)
JP (1) JP5558810B2 (https=)
KR (1) KR20090008459A (https=)
CN (1) CN101548012A (https=)
AR (1) AR060862A1 (https=)
AU (1) AU2007248784B2 (https=)
BR (1) BRPI0711193A2 (https=)
CA (1) CA2651348A1 (https=)
DO (1) DOP2007000089A (https=)
EA (1) EA017291B1 (https=)
IL (1) IL194482A0 (https=)
MX (1) MX2008013863A (https=)
NL (1) NL2000626A1 (https=)
NZ (1) NZ571692A (https=)
PE (1) PE20080397A1 (https=)
SG (1) SG171670A1 (https=)
TW (1) TW200801036A (https=)
UY (1) UY30324A1 (https=)
WO (1) WO2007130302A2 (https=)
ZA (1) ZA200809394B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20105110B (en) * 2004-08-03 2010-11-10 Transtech Pharma Inc Rage fusion proteins and their use
SG161242A1 (en) * 2004-08-03 2010-05-27 Transtech Pharma Inc Rage fusion proteins and methods of use
JP5314428B2 (ja) * 2005-12-23 2013-10-16 ジーコデール システムズ アクチボラゲット 測位用パターン
EP1989227A2 (en) * 2006-02-09 2008-11-12 Transtech Pharma, Inc. Rage fusion proteins and methods of use
SG171670A1 (en) 2006-05-05 2011-06-29 Transtech Pharma Inc Rage fusion proteins, formulations, and methods of use thereof
WO2008100470A2 (en) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
US20100216977A1 (en) * 2007-02-15 2010-08-26 Kyushu University, National University Corporation Therapeutic agent for interstitial pulmonary disease comprising anti-hmgb-1 antibody
JP5225109B2 (ja) * 2007-02-15 2013-07-03 国立大学法人 熊本大学 ヒトｈｍｇｂ−１に特異的に結合する抗体を有効成分として含有する治療剤
WO2008099917A1 (ja) * 2007-02-15 2008-08-21 Fukuoka University 抗hmgb-1抗体を含む臓器移植拒絶抑制剤
KR101595634B1 (ko) 2007-06-14 2016-02-18 갈락티카 파마슈티칼스, 인크. Ｒａｇｅ 융합 단백질
AU2010240569A1 (en) * 2009-04-20 2011-10-20 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
WO2011102845A1 (en) * 2010-02-18 2011-08-25 Transtech Pharma, Inc. Rage fusion protein compositions and methods of use
WO2013074820A1 (en) 2011-11-16 2013-05-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Immunogenic tumor associated stromal cell antigen peptides and methods of their use
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
PL2925338T3 (pl) * 2012-11-28 2019-11-29 Nono Inc Liofilizowana formulacja TAT-NR2B9C
EP3077823B1 (en) 2013-12-05 2019-09-04 The Broad Institute, Inc. Compositions and methods for identifying and treating cachexia or pre-cachexia
JP6617110B2 (ja) * 2014-10-01 2019-12-04 国立研究開発法人農業・食品産業技術総合研究機構 遺伝子組換えカイコにより生産したビオチン化酸化ｌｄｌ受容体・終末糖化産物受容体
EP3822291A1 (en) 2015-06-10 2021-05-19 The Broad Institute Inc. Antibodies, compounds and screens for identifying and treating cachexia or pre-cachexia
WO2017106196A1 (en) 2015-12-14 2017-06-22 The Broad Institute, Inc. Compositions and methods for treating cardiac dysfunction
CN112699601B (zh) * 2020-12-28 2022-05-31 电子科技大学 一种传感器网络数据的空时重构方法
US20230246158A1 (en) * 2022-02-02 2023-08-03 Enevate Corporation Cycle life in si/li batteries using high temperature deep discharge cycling

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
SE9201073D0 (sv) 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5656261A (en) 1995-01-18 1997-08-12 The Picower Institute For Medical Research Preventing and reversing advanced glycosylation endproducts
DE69629176T2 (de) 1995-01-18 2004-06-03 Alteon Inc. Verwendung von thiazoliumverbindungen zum verhindern und umkehren der bildung von endprodukten der fortgeschrittenen glykosylierung
FI119756B (fi) 1995-01-18 2009-03-13 Alteon Inc Tiatsoliumyhdisteiden käyttö pitkälle edenneen glykosylaation lopputuotteiden muodostumisen estossa ja suunnan muutoksessa
CA2217572A1 (en) 1995-04-05 1996-10-10 The Picower Institute For Medical Research Agents for binding to advanced glycosylation endproducts, and methods of their use
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AU1832797A (en) 1996-01-26 1997-08-20 Trustees Of Columbia University In The City Of New York, The A polypeptide from lung extract which binds amyloid-beta peptide
WO1997039121A1 (en) 1996-04-16 1997-10-23 Schering Aktiengesellschaft Advanced glycosylation end-product receptor peptides and uses therefor
US5864018A (en) 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
US7081241B1 (en) 1998-10-06 2006-07-25 The Trustees Of Columbia University In The City Of New York Extracellular rage binding protein (EN-RAGE) and uses thereof
US7258857B2 (en) 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US6555651B2 (en) 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
US6790443B2 (en) 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
JP2001514661A (ja) 1997-03-11 2001-09-11 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病の処置における使用のための薬剤の同定
US7101838B2 (en) 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
MY131805A (en) 1997-09-18 2007-09-28 Biogen Idec Inc Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
US6380165B1 (en) 1997-09-19 2002-04-30 The Picower Institute For Medical Research Immunological advanced glycation endproduct crosslink
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6323218B1 (en) 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6465422B1 (en) 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
WO2000018970A1 (fr) 1998-09-29 2000-04-06 Asahi Kasei Kabushiki Kaisha Procede de commande de liberation de granules
SK4272001A3 (en) * 1998-10-05 2003-02-04 Pharmexa As Methods for therapeutic vaccination
US6753150B2 (en) 1998-10-05 2004-06-22 The Trustees Of Columbia University In The City Of New York Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage
AU765719B2 (en) 1998-10-06 2003-09-25 Trustees Of Columbia University In The City Of New York, The Extracellular novel rage binding protein (EN-RAGE) and uses thereof
US6197294B1 (en) 1998-10-26 2001-03-06 Neurotech S.A. Cell surface molecule-induced macrophage activation
US6605642B2 (en) 1999-04-05 2003-08-12 City Of Hope Inhibitors of formation of advanced glycation endproducts (AGES)
US6787566B2 (en) 1999-04-05 2004-09-07 City Of Hope Breakers of advanced glycation endproducts
US6589944B1 (en) 1999-04-05 2003-07-08 City Of Hope Breakers of advanced glycation endproducts
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
US6835200B2 (en) 1999-06-22 2004-12-28 Ndo Surgical. Inc. Method and devices for tissue reconfiguration
FR2797402B1 (fr) 1999-07-15 2004-03-12 Biomerieux Stelhys Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
CA2382095A1 (en) 1999-08-13 2001-02-22 The Trustees Of Columbia University In The City Of New York Methods of inhibiting binding of .beta.-sheet fibril to rage and consequences thereof
EP1219639A4 (en) 1999-09-08 2009-03-25 Toray Industries CIPO - Patent
US20050170382A1 (en) 1999-10-06 2005-08-04 The Trustees Of Columbia University In The City Of New York. RAGE-related compositions
CA2356207C (en) 1999-10-21 2012-10-09 Case Western Reserve University Gene expression profiling of inflammatory bowel disease
JP2003516150A (ja) 1999-12-08 2003-05-13 ジェンセット 潜在性分泌タンパク質をコードする全長ヒトｃＤＮＡ
US6716635B2 (en) 2000-04-14 2004-04-06 University Of Kentucky Research Foundation Method for identifying regulators of protein-advanced glycation end product (protein-AGE) formation
AU2001255436A1 (en) 2000-04-17 2001-10-30 Transtech Pharma Protein expression system arrays and use in biological screening
US6563015B1 (en) 2000-08-14 2003-05-13 The Trustees Of Columbia University In The City Of New York Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) and mutant APP in brain and uses thereof
US6825164B1 (en) 2000-08-14 2004-11-30 The Trustees Of Columbia University In The City Of New York Method to increase cerebral blood flow in amyloid angiopathy
CA2424246A1 (en) 2000-10-02 2002-04-11 Shianlen Cahoon Methods and compositions for the treatment of inflammatory diseases
AU2002213192A1 (en) 2000-10-13 2002-04-22 The Trustees Of Columbia University In The City Of New York A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
US20050244849A1 (en) 2000-12-15 2005-11-03 Genetics Institute, Llc Screening assays for rheumatoid arthritis
PL366250A1 (en) 2000-12-29 2005-01-24 Reddy Us Therapeutics, Inc. Detection of compounds that modulate inflammatory responses
CN100522242C (zh) 2001-02-19 2009-08-05 默克专利有限公司 具有降低的免疫原性的人工蛋白质
JP3837494B2 (ja) 2001-03-19 2006-10-25 国立大学法人金沢大学 可溶型ｒａｇｅタンパク質
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
EP1575513A4 (en) 2002-08-16 2007-04-04 Wyeth Corp COMPOSITIONS AND METHODS FOR TREATING RAGE-ASSOCIATED DISEASES
US8067371B2 (en) 2003-05-09 2011-11-29 The Trustees Of Columbia University In The City Of New York RAGE G82S-related methods and compositions for treating inflammatory disorders
US20050008649A1 (en) 2003-06-02 2005-01-13 University Of Miami Chimeric molecules and methods of use
ZA200601810B (en) 2003-09-05 2008-05-28 Univ Columbia Rage-related methods and compositions for treating glomerular injury
US20070167360A1 (en) 2003-10-31 2007-07-19 Yan Shi D Methods for treating multiple sclerosis
US20060012414A1 (en) * 2004-07-15 2006-01-19 Texas Instruments Incorporated Circuit and method for generating a polyphase clock signal and system incorporating the same
WO2006012414A2 (en) 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Novel polyadenylation signal for use in expression vectors
EP1771565B1 (en) 2004-07-20 2012-09-05 The Feinstein Institute for Medical Research Rage protein derivatives
SG161242A1 (en) 2004-08-03 2010-05-27 Transtech Pharma Inc Rage fusion proteins and methods of use
GEP20105110B (en) 2004-08-03 2010-11-10 Transtech Pharma Inc Rage fusion proteins and their use
WO2006036922A2 (en) 2004-09-27 2006-04-06 Centocor, Inc. Srage mimetibody, compositions, methods and uses
US20080207499A1 (en) 2005-06-29 2008-08-28 Gaetano Barile Rage-related methods for treating and preventing diabetic retinopathy
EP1989227A2 (en) 2006-02-09 2008-11-12 Transtech Pharma, Inc. Rage fusion proteins and methods of use
SG171670A1 (en) 2006-05-05 2011-06-29 Transtech Pharma Inc Rage fusion proteins, formulations, and methods of use thereof
WO2008100470A2 (en) 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins

Similar Documents

Publication Publication Date Title
JP2009536201A5 (https=)
US20230060574A1 (en) Serum albumin binders
JP7417421B2 (ja) 改善された血清アルブミン結合性免疫グロブリン単一可変ドメイン
AU2016357460B2 (en) Improved serum albumin binders
AU2018209150B2 (en) Improved serum albumin binders
AU2016351710B2 (en) Improved serum albumin-binding immunoglobulin variable domains
KR102843708B1 (ko) 이중특이적 항체 작제물을 포함하는 약제학적 조성물
US20100158925A1 (en) Lyophilized formulations of anti-egfr antibodies
JP2017538395A5 (https=)
JP2016534052A5 (https=)
JP2021504372A5 (https=)
KR20170010893A (ko) 아미노 말단 면역글로불린 융합 단백질 및 이의 조성물을 구축하는 방법
RU2007119989A (ru) Композиции, слитые конструкции и конъюгаты plad домена
CN112390884B (zh) Semaphorin7A单克隆抗体及其在制备用于治疗炎症疾病药物方面的应用
JP2024526820A5 (https=)
JP2025116068A (ja) 腎臓活性融合タンパク質及びそれを使用する治療方法
HK40117444A (en) Improved serum albumin binders
HK40118030A (en) Improved serum albumin binders
HK40017968B (en) Improved serum albumin binders
HK40017968A (en) Improved serum albumin binders
CN111902189A (zh) 用于治疗儿科患者中的癌症的雷莫芦单抗
HK40018516B (en) Improved serum albumin binders
HK40018516A (en) Improved serum albumin binders